Structure Therapeutics appoints Matthew Lang as COO and General Counsel

Structure Therapeutics Inc.

Lang effective April 15, 2026; salary $560,000/yr with 40% target bonus.
Equity grant: options for 223,776 ordinary shares (74,592 ADSs), time-based RSUs for 184,614 ordinary shares, and PSUs for 46,155 ordinary shares at target.
Former Chief Legal Officer at Metsera, where he helped guide the up to $10B Pfizer acquisition; also held exec roles at Lyell, Myovant, and Gilead.
Company advancing aleniglipron into Phase 3 for obesity; Lang to support operational foundation and strategic priorities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.